Antonio (Anthony) Giovinazzo has served as our Executive Chairman and as a member of our board of directors since May 2018, as a director of Sublimity Therapeutics Holdco Limited and following the corporate reorganization also as a director of Sublimity Therapeutics plc. From November 2009 to October 2016, Mr. Giovinazzo served as the President, Chief Executive Officer and a director of Cynapsus Therapeutics Inc., a clinical-stage pharmaceutical company. From April 2006 to November 2009, Mr. Giovinazzo served as the Chief Executive Officer of Cervelo Pharmaceuticals Ltd., a biopharmaceutical company. From 2002 to 2006, he served as Chief Executive Officer of Cita NeuroPharmaceuticals Inc., a biopharmaceutical company. Mr. Giovinazzo obtained a Chartered Director (C.Dir.) and Audit Committee Certification (A.C.C.) from The Director’s College (where he was also a faculty member) in 2006 and 2011, respectively. Mr. Giovinazzo completed his M.B.A. at IMD Geneva, Switzerland; Graduate Certificate Studies in Canadian Law (Securities & Taxation) at Osgoode Hall Law School, York University; and a B.A. in Economics and Accounting, at McMaster University. He also attended the Harvard Business School Executive Program: Leadership and Strategy in Pharmaceuticals and Biotech in 2006. We believe Mr. Giovinazzo is qualified to serve on our board of directors based on his extensive experience with clinical stage pharmaceutical companies.
Albert Agro has served as our President and Chief Executive Officer and as a member of Board of Directors since May 2018, as a director of Sublimity Therapeutics Holdco Limited and following the corporate reorganization also as a director of Sublimity Therapeutics plc. From October 2016 to May 2018, Dr. Agro was a founder and served as the Executive Vice President, Clinical Development of GRi Bio, a clinical-stage biotechnology company. From August 2010 to October 2016, Dr. Agro served as the Chief Medical Officer of Cynapsus Therapeutics Inc., a clinical-stage pharmaceutical company. From September 2008 to August 2010, Dr. Agro was the President and Chief Executive Officer of HNZ Strategic Holdings, Inc., a pharmaceutical and biotech consulting firm developing treatments for serious diseases. From September 2007 to December 2009, Dr. Agro held the position of Executive Vice President, Drug Development of TransTech Pharma, a pharmaceutical company. Since September 1996, he has been an Assistant Professor, Department of Pathology and Molecular Medicine at McMaster University. Dr. Agro completed his B.S. from the University of Guelph, and his Ph.D. from the Department of Medicine at McMaster University. We believe Dr. Agro is qualified to serve on our board of directors based on based on his extensive experience with clinical stage pharmaceutical companies.
Jesse Hall has served as our Chief Medical Officer since July 2018. From September 2013 to January 2018, Dr. Hall served as an Executive Medical Director of Ardea Biosciences Inc., a biotechnology company. From October 2009 to September 2013, Dr. Hall held the position of Medical Director for Amgen Inc., a biopharmaceutical company. From 2004 to 2009, Dr. Hall held multiple positions of increasing responsibilities at Abbott Laboratories, a multinational medical devices and health care company. Dr. Hall completed his B.A. in Ocean Studies and Economics from the University of San Diego and his M.D. from the College of Medicine at the University of Oklahoma.
Linda Rubinstein has served as Sublimity’s Chief Financial Officer since January 2020. Linda is a partner of FLG Partners, a CFO services firm. Other CFO or interim CFO roles have included Apexigen, ArmaGen, Five Prime Therapeutics, Kezar Life Sciences, EpiBiome, Tunitas, True North Therapeutics, Retrotope, PaxVax, iPierian (acquired by Bristol-Myers Squibb), Ingenuity (acquired by QIAGEN), and Solexa (acquired by Illumina). Earlier, Ms. Rubinstein served as Vice President of Finance for ChemoCentryx. Ms. Rubinstein began her career as an investment banker, most recently as Senior Vice President of Lehman Brothers’ Global Healthcare Investment Banking Group.
Ms. Rubinstein has over 30 years of operational, financial, and capital markets experience. As a CFO, Ms. Rubinstein has led the finance functions at research- and commercial-stage companies, successfully completed financing and M&A transactions, and contributed to operations and strategy. As an investment banker, Ms. Rubinstein completed over 30 transactions, raising over $5 billion in capital for companies. Ms. Rubinstein earned her Bachelor and Master’s degrees in Economics (summa cum laude and Phi Beta Kappa) from the University of California, Los Angeles.
Ross Maclean has served as our Chief Regulatory Officer and Executive Vice President, Translation Medicine since January 2020. Prior to this role, Dr. Maclean served as our Executive Vice President Global Regulatory Affairs and Compliance from May 2018 to January 2020. From February 2016 to March 2017, Dr. Maclean held the position of Vice President, Global Regulatory Affairs of Cynapsus Therapeutics Inc., a clinical-stage pharmaceutical company. From November 2011 to January 2016, Dr. Maclean was the Senior Vice President, Scientific and Regulatory Affairs at Apotex Inc., a pharmaceutical company. Dr. Maclean completed his BSc (Hons) in Physiology with Pharmacology and his PhD in Pharmacology at Southampton University.
Brendan Cahill has served as our Global Head of Corporate Affairs, General Counsel and Secretary since January 2019. From 1995 to December 2018, Mr. Cahill served as a Partner at William Fry, a national Ireland-based law firm, and was the Managing Partner of the firm from 2004 to 2008. Mr. Cahill is a graduate of the College of Commerce Dublin and is a member of the Incorporated Law Society of Ireland
Stephen Ireland has served as our Executive Vice President, Global Business Development since January 2019. From August 2013 to December 2018, Mr. Ireland served as a Partner at Roadmap Capital Inc., an investment firm. From February 2002 to April 2013, Mr. Ireland held the position of Senior Vice President, Business Development at TransTech Pharma Inc., a clinical-stage pharmaceutical company. Mr. Ireland completed his B.S. in Biological Sciences at Brock University.
Thomas Shelly has served as our General Manager, Ireland since May 2018. From 2001 to 2018, Mr. Shelly also served as the Managing Director of Cambridge Clinical Research, a site management services provider company. From 1989 to 2001, Mr. Shelly held the position of Vice President of Operations and Finance at Tecan U.S., Inc., an automated laboratory instruments and solution company. Mr. Shelly completed his Diploma of International Studies from the Davidson College; his B.Comm. from the University College Dublin; and his M.B.A. from the Kenan Flagler Business School at the University of North Carolina. Mr. Shelly is a Fellow of the Institute of Chartered Accountants in Ireland.
We are led by a management team with substantial scientific, drug development, and commercialization experience across relevant disciplines including immunology and gastroenterology. Our executives have held diverse roles leading research, clinical development, pharmacovigilance, medical affairs, strategy, corporate development and operational functions at large biopharmaceutical companies, venture-backed start-ups, public biotechnology companies, and academia having worked at companies such as Abbott, Amgen, Bayer, Boehringer Ingelheim, Cynapsus and Sunovion. Members of our leadership team have been involved in the discovery, development and commercialization of multiple marketed products across various therapeutic areas, including Cipro, Flomax, Humira, Kynmobi, SangCya, and Thymoglobulin. Our leadership is complemented by a team of researchers and biologics development experts, the majority of whom hold PhD, MD, or other advanced graduate degrees.
Since our founding, we have raised more than €70 million in funding and are supported by leading investors including HBM Partners, Longitude Capital, and OrbiMed.
Anthony J. Giovinazzo
Executive Chairman MBA,
C.Dir. & A.C.C.
(see management section)
- Albert Agro, PhD President and Chief Executive Officer
- Alexander Asam, PhD
- Josh Richardson, MD
- David Bonita, MD
- Michael Parker
- Roderick Ryan
Sublimity has a strategic collaboration with Dr. Falk Pharma GmbH that includes development funding, milestone payments and tiered royalties for the future development and commercialization of ST-0529 and related products in Europe.
Dr. Falk Pharma GmbH is one of the leading companies worldwide in gastroenterology with its products being sold in more than 60 countries. The company’s pharmaceuticals are used successfully to treat inflammatory bowel disease, cholestatic liver disease, irritable bowel syndrome, constipation, and for colon cleansing prior to colonoscopies.
Sublimity has a partnered with Pharmascience for development and commercialization of ST-0529 and related products in Canada.
Pharmascience Inc. is a full-service, privately owned pharmaceutical company that has strong roots in Canada and a growing global reach, with product distribution in over 60 countries.